Item 1.01 Entry into a Material Definitive Agreement

Savient Pharmaceuticals, Inc. (the "Company") entered into a commercial supply agreement with Bio-Technology General (Israel) Ltd. ("BTG-Israel") on March 20, 2007 to serve as the initial primary bulk active pharmaceutical ingredient, or API, manufacturer of Krystexxa™ (pegloticase), formerly referred to as Puricase®, as well as to provide regulatory support with respect to the biologics licensing application ("BLA") filing for the approval of Krystexxa. Pursuant to the BTG-Israel commercial supply agreement, the Company has agreed to certain minimum purchase obligations, the cost of which may decrease depending on its purchase requirements. The commercial supply agreement with BTG-Israel may not be terminated by either party until 2018. Beginning in 2015, either party may terminate the agreement with three years advance notice.
The Company entered into an exclusive supply agreement with NOF Corporation ("NOF") on May 3, 2007. Pursuant to the agreement, NOF will supply the Company with polyethylene glycol ("PEG"), an ingredient in Krystexxa. Pursuant to the terms of the agreement with NOF, the Company has agreed to make future minimum purchases of PEG. The agreement with NOF has an initial term ending in May 2017. It may be terminated for convenience by either party with two years prior notice, or for breach or insolvency. If either party terminates this agreement in specified circumstances, the Company may require NOF to continue to supply PEG to it for four years following notice of termination.

Item 9.01 Financial Statements and Exhibits

d) Exhibits See Exhibit Index attached hereto.

---